Quick Search:       Advanced Search
Chinese Version 
Online office
Journal Online
Download
Top
Links

扫描微信二维码,获取更多信息
Effects of Kaixin Jieyu Decoction (开心解郁汤) on Behavior and Glial Fibrillary Acidic Protein Expression in Cerebral Hippocampus of A Rat Vascular Depression Model
  
View Full Text  View/Add Comment  Download reader
KeyWord:vascular depression, Kaixin Jieyu Decoction, behavior, glial fibrillary acidic protein, Chinese meicine
Author NameAffiliationE-mail
ZHANG Xian-hui, WANG Yan-yun, ZHANG Ying   
HUANG Shi-jing Traditional Chinese Medicine Research and Development Center, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing (100053), China gamhsj@126.com 
Hits: 958
Download times: 73
Abstract:
      Objective: To explore the effects and anti-depression mechanisms of Kaixin Jieyu Decoction (开心解郁汤, KJD). Methods: The rat vascular depression (VD) model was established by ligation of bilateral common carotid arteries (LBCCA) combined with chronic unpredictable mild stress (CUMS). Forty Wistar rats were randomly divided into sham, VD model, VD + high-dose KJD [15.4 g/(kg?d) of crude drug], VD + medium-dose KJD [7.7 g/(kg?d) of crude drug], and VD + fluoxetine [2.4 mg/(kg?d)] groups (n=8 in each group), and the treatments lasted for 21 days. Changes of behavior and hippocampus pathology were observed. The level of glial fibrillary acidic protein (GFAP) protein and mRNA in hippocampus was detected respectively by immunohistochemistry and real-time polymerase chain reaction. Results: Compared with the sham group, rats in model group showed a variety of behavioral obstacles, including a significant reduction in sucrose consumption percentage, horizontal and vertical activity scores in open-field tests (P<0.05 or P<0.01), pathological damage like neuronal degeneration, necrosis, and a significant decrease of GFAP protein and mRNA in hippocampus (P<0.01); compared with the model group, rats in the high-dose KJD group, medium-dose KJD group and fluoxetine group obtained notable higher behavioral scores, and pathological injury lessened in hippocampus with a increased expression of GFAP protein and mRNA (P<0.05 or P<0.01); compared with the medium-dose KJD group and fluoxetine group, GFAP mRNA in high-dose KJD group expressed higer (P<0.05). Conclusion: LBCCA combined with CUMS may cause depression-like behavioral changes resulting in the VD model of rats whose depression state can be ameliorated by KJD, and the mechanism of cerebral protection is related possibly with promoting expression of GFAP in hippocampus.
Close